Not All Potential Drugs Get Their Day in the Sun.

In this episode, David Katz talks about how this company focuses on developing medicines that can alleviate the side effects of existing medications, specifically in the context of steroids. He discusses the challenges of balancing commercial interests with scientific advancements, Sparrow Pharmaceuticals' strategy of acquiring deprioritized molecules, targeting HSD-1 for safer steroids, and their focus on Polymyalgia Rheumatica.

Tune in and learn more about Sparrow Pharmaceutical’s breakthrough approach to medication development!

Click this link to the show notes, transcript, and resources: outcomesrocket.health